{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:55Z","timestamp":1787009395373,"version":"build-2736575974"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucocorticoids have been a cornerstone of treatment for inflammatory and autoimmune kidney diseases for almost 70\u2009years, yet it is fair to say, we still do not know how \u2018best\u2019 to use them. Significant adverse events are associated with their continued use, which contribute to premature patient mortality. Steroid avoidance or minimization is possible and has been tested in various glomerular diseases, as a result of novel agents or innovative regimens using established therapeutics. It is now time to seriously address our use of steroids and educate physicians on better ways of managing inflammatory kidney diseases.<\/jats:p>","DOI":"10.1093\/ndt\/gfaa267","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T16:52:49Z","timestamp":1601398369000},"page":"1212-1217","source":"Crossref","is-referenced-by-count":9,"title":["Steroids as treatment for glomerulonephritis: time for a rethink"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0160-7771","authenticated-orcid":false,"given":"Heidy","family":"Hendra","sequence":"first","affiliation":[{"name":"UCL Department of Renal Medicine, Royal Free Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Salama","sequence":"additional","affiliation":[{"name":"UCL Department of Renal Medicine, Royal Free Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"key":"2022062300072585400_gfaa267-B1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40620-016-0308-3","article-title":"Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance","volume":"30","author":"Lieberman","year":"2017","journal-title":"J Nephrol"},{"key":"2022062300072585400_gfaa267-B2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.3.5720.421","article-title":"Controlled trial of prednisone in adult patients with the nephrotic syndrome","volume":"3","author":"Black","year":"1970","journal-title":"Br Med J"},{"key":"2022062300072585400_gfaa267-B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9681(62)90100-5","article-title":"Corticosteroid therapy of glomerulonephritis and the nephrotic syndrome: a review","volume":"15","author":"Adams","year":"1962","journal-title":"J Chronic Dis"},{"key":"2022062300072585400_gfaa267-B4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0002-9343(54)90255-7","article-title":"Wegener\u2019s granulomatosis","volume":"17","author":"Fahey","year":"1954","journal-title":"Am J Med"},{"key":"2022062300072585400_gfaa267-B5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJM195005252422105","article-title":"The clinical usefulness of ACTH and cortisone","volume":"242","author":"Thorn","year":"1950","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B6","first-page":"537","article-title":"The effect of cortisone on the lesions of periarteritis nodosa","volume":"27","author":"Baggenstoss","year":"1951","journal-title":"Am J Pathol"},{"key":"2022062300072585400_gfaa267-B7","first-page":"495","article-title":"Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis","volume":"57","author":"Pollak","year":"1961","journal-title":"J Lab Clin Med"},{"key":"2022062300072585400_gfaa267-B8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"2022062300072585400_gfaa267-B10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.1973.14","article-title":"Anti-glomerular basement membrane antibody-induced glomerulonephritis","volume":"3","author":"Wilson","year":"1973","journal-title":"Kidney Int"},{"key":"2022062300072585400_gfaa267-B11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(76)93089-0","article-title":"Immunosuppression and plasma-exchange in the treatment of Goodpasture\u2019s syndrome","volume":"307","author":"Lockwood","year":"1976","journal-title":"Lancet"},{"key":"2022062300072585400_gfaa267-B12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"2022062300072585400_gfaa267-B13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2022062300072585400_gfaa267-B14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40620-019-00602-5","article-title":"Prevention of complications from use of conventional immunosuppressants: a critical review","volume":"32","author":"Ponticelli","year":"2019","journal-title":"J Nephrol"},{"key":"2022062300072585400_gfaa267-B15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B16","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.2019-00153","article-title":"Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England","volume":"104","author":"Mebrahtu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2022062300072585400_gfaa267-B17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/ajt.12313","article-title":"Association between steroid dosage and death with a functioning graft after kidney transplantation","volume":"13","author":"Opelz","year":"2013","journal-title":"Am J Transplant"},{"key":"2022062300072585400_gfaa267-B18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022062300072585400_gfaa267-B21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"2022062300072585400_gfaa267-B22","doi-asserted-by":"crossref","first-page":"e000889","DOI":"10.1136\/rmdopen-2018-000889","article-title":"Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study","volume":"5","author":"Buttgereit","year":"2019","journal-title":"RMD Open"},{"key":"2022062300072585400_gfaa267-B23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2019060618","article-title":"Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage and crescentic glomerulonephritis","volume":"31","author":"Antonelou","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B24","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1681\/ASN.2010080892","article-title":"Neutrophil serine proteases promote IL-1beta generation and injury in necrotizing crescentic glomerulonephritis","volume":"23","author":"Schreiber","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2016010060","article-title":"Investigations of glucocorticoid action in GN","volume":"28","author":"Kuppe","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B27","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1681\/ASN.2018030324","article-title":"Podocyte-specific induction of kruppel-like factor 15 restores differentiation markers and attenuates kidney injury in proteinuric kidney disease","volume":"29","author":"Guo","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfq617","article-title":"The podocyte as a direct target of immunosuppressive agents","volume":"26","author":"Schonenberger","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300072585400_gfaa267-B29","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"2022062300072585400_gfaa267-B30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022062300072585400_gfaa267-B31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kez001","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford"},{"key":"2022062300072585400_gfaa267-B32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B35","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"2022062300072585400_gfaa267-B37","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2022062300072585400_gfaa267-B39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"key":"2022062300072585400_gfaa267-B40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022062300072585400_gfaa267-B41","first-page":"177","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int"},{"key":"2022062300072585400_gfaa267-B42","doi-asserted-by":"crossref","first-page":"93438","DOI":"10.18632\/oncotarget.21833","article-title":"Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"2022062300072585400_gfaa267-B43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/nep.12744","article-title":"Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease","volume":"21","author":"Papakrivopoulou","year":"2016","journal-title":"Nephrology (Carlton"},{"key":"2022062300072585400_gfaa267-B44","author":"TURING","year":"2019"},{"key":"2022062300072585400_gfaa267-B45","author":"RIFIREINS","year":"2019"},{"key":"2022062300072585400_gfaa267-B46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"2022062300072585400_gfaa267-B47","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2022062300072585400_gfaa267-B48","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2022062300072585400_gfaa267-B49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2022062300072585400_gfaa267-B50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2022062300072585400_gfaa267-B51"},{"key":"2022062300072585400_gfaa267-B52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2022062300072585400_gfaa267-B53","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.431","article-title":"Spleen tyrosine kinase (SYK) inhibition in IgA nephropathy: a global, phase II, randomised placebo-controlled trial of fostamatinib","volume":"4","author":"Tam","year":"2019","journal-title":"Kidney Int Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/7\/1212\/44138350\/gfaa267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/7\/1212\/44138350\/gfaa267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T20:08:13Z","timestamp":1655928493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/7\/1212\/5981971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,11,14]]},"published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa267","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2020,11,14]]}}}